Global Pseudomonas Diagnostics Market, 2019-2023: Emerging Opportunities in US, Europe, Japan--Supplier Shares and Strategies, Sales Segment Forecasts, Innovative Technologies and Tests

Global Pseudomonas Diagnostics Market, 2019-2023: Emerging Opportunities in US, Europe, Japan--Supplier Shares and Strategies, Sales Segment Forecasts, Innovative Technologies and Tests

  • June 2019 •
  • 198 pages •
  • Report ID: 5783975 •
  • Format: PDF
Global Pseudomonas Diagnostics Market, 2019-2023: Emerging Opportunities in US, Europe, Japan--Supplier Shares and Strategies, Sales Segment Forecasts, Innovative Technologies and Tests

The report presents a detailed analysis of the Pseudomonas diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Pseudomonas definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:

     - Hospitals
     - Commercial/Private Labs
     - Physician Offices
     - Public Health Labs

Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.

Contains 198 pages and 7 tables


Companies Profiled
Competitive Assessments

- Abbott
- Affymetrix
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Cepheid
- Diamedix
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujirebio
- Grifols
- GSK Biologicals
- Hologic
- Leica Biosystems
- Lonza
- Ortho-Clinical Diagnostics
- PerkinElmer
- Qiagen
- Roche
- Scienion
- Sequenom
- SeraCare
- Siemens Healthineers
- Takara Bio
- Thermo Fisher
- Wako